公开(公告)号：US20180125852A1

公开(公告)日：2018-05-10

申请号：US15572456

申请日：2016-05-09

申请人： MEMORIAL SLOAN KETTERING CANCER CENTER

发明人： Daniela Francis Quail ,  Johanna Alexandra Joyce ,  Robert Lyle Bowman

IPC分类号： A61K31/5377 ,  A61K31/519 ,  A61K31/517 ,  A61K31/496 ,  A61K31/47 ,  A61K31/4406 ,  A61K31/437 ,  A61K31/428 ,  A61K31/426 ,  A61K31/423 ,  A61K31/4184 ,  A61K31/416 ,  A61K45/06 ,  A61P25/00 ,  A61P35/00

CPC分类号： A61K31/5377 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/423 ,  A61K31/426 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4406 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/517 ,  A61K31/519 ,  A61K45/06 ,  A61K2300/00 ,  A61P25/00 ,  A61P35/00

摘要： In certain embodiments the present invention provides methods useful in the treatment of glioma, such as glioblastoma, such methods comprising administering to a subject in need thereof a CSF-IR inhibitor together with one or more additional active agents such as IGF-IR inhibitors, PI3K inhibitors, IL4 inhibitors, NFAT inhibitors, and/or Stat6 inhibitors. In certain embodiments the present invention provides pharmaceutical compositions comprising a CSF-IR inhibitor together with one or more of such additional active agents.

公开(公告)号：US20180110774A1

公开(公告)日：2018-04-26

申请号：US15570042

申请日：2016-04-28

申请人： STC.UNM

发明人： Laura V. Gonzalez Bosc ,  Levi D. Maston ,  Thomas Resta

IPC分类号： A61K31/495 ,  A61P9/12 ,  A61K45/06 ,  A61K9/00

CPC分类号： A61K31/495 ,  A61K9/0078 ,  A61K31/192 ,  A61K31/343 ,  A61K31/426 ,  A61K31/4985 ,  A61K31/506 ,  A61K31/519 ,  A61K31/5578 ,  A61K45/06 ,  A61P9/12 ,  C07D277/38 ,  C07D295/108 ,  A61K2300/00

摘要： Methods and composition for treating or preventing pulmonary hypertension are provided. In certain aspects, compounds that inhibit TH17 cell maturation or activity, such as retinoic acid receptor-related orphan nuclear receptor (ROR) inhibitors, are used to for the treatment of pulmonary hypertension.

公开(公告)号：US20180110740A1

公开(公告)日：2018-04-26

申请号：US15546191

申请日：2016-01-26

申请人： Mayo Foundation for Medical Education and Research

发明人： Gaurang S. Daftary

IPC分类号： A61K31/122 ,  A61P15/00 ,  A61K31/60 ,  A61K31/426 ,  A61K31/09

CPC分类号： A61K31/122 ,  A61K31/09 ,  A61K31/12 ,  A61K31/365 ,  A61K31/426 ,  A61K31/60 ,  A61P15/00

摘要： This document provides methods and materials for treating endometriosis. For example, methods and materials for using histone acetyl transferase inhibitors (e.g., garcinol) to treat endometriosis are provided.

公开(公告)号：US09937157B2

公开(公告)日：2018-04-10

申请号：US15010212

申请日：2016-01-29

申请人： Takeda Pharmaceuticals U.S.A., Inc.

发明人： Rajneesh Taneja ,  Vijay Gupte ,  Majid Vakilynejad

IPC分类号： A61K31/426 ,  A61K9/00 ,  A61K9/28 ,  A61K9/20 ,  A61K9/50 ,  A61K9/16 ,  A61K9/24

CPC分类号： A61K31/426 ,  A61K9/0004 ,  A61K9/0053 ,  A61K9/1629 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/209 ,  A61K9/2833 ,  A61K9/5026 ,  A61K9/5047 ,  A61K9/5078 ,  A61K9/5084

摘要： The present disclosure relates to novel dosage forms of xanthine oxidoreductase inhibitors.

公开(公告)号：US20180092884A1

公开(公告)日：2018-04-05

申请号：US15841777

申请日：2017-12-14

申请人： Genfit

发明人： Raphael Darteil ,  Robert Walczak ,  Carole Belanger ,  Emilie Negro ,  Pierre Daubersies ,  Philippe Delataille

IPC分类号： A61K31/426 ,  A61K45/06

CPC分类号： A61K31/426 ,  A61K45/06

摘要： The present invention relates to the compound [2-[(5-nitro-1, 3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.

公开(公告)号：US09931353B2

公开(公告)日：2018-04-03

申请号：US14704445

申请日：2015-05-05

申请人： Amicus Therapeutics, Inc.

发明人： Brandon Alan Wustman ,  Kenneth Valenzano ,  Robert Boyd

IPC分类号： A61K31/7008 ,  A61K31/445 ,  A61K38/17 ,  A61K31/426 ,  A61K31/429

CPC分类号： A61K31/7008 ,  A61K31/426 ,  A61K31/429 ,  A61K31/445 ,  A61K38/1709 ,  G06F19/00

摘要： The present invention relates to a method for treating an individual having Cerebral Amyloid Angiopathy by using pharmacological chaperones to increase the activity of gangliosidase and/or sialidase enzymes involved in ganglioside catabolism.

公开(公告)号：US09920042B2

公开(公告)日：2018-03-20

申请号：US14430604

申请日：2013-09-27

申请人： Universite de Droit et de la Sante de Lille 2

发明人： Nicolas Willand ,  Benoit Deprez ,  Alain Baulard ,  Priscille Brodin ,  Olivier Sperando ,  Vincent Villeret ,  Baptiste Villemagne

IPC分类号： C07D277/26 ,  C07D277/30 ,  C07D417/04 ,  C07D213/81 ,  C07D249/06 ,  C07D249/08 ,  C07D271/06 ,  C07D277/56 ,  C07D277/66 ,  C07D285/08 ,  C07D285/12 ,  C07D291/04 ,  C07C255/57 ,  C07C311/37 ,  C07C247/18 ,  A61K31/155 ,  A61K31/175 ,  A61K31/4192 ,  A61K31/421 ,  A61K31/4245 ,  A61K31/426 ,  A61K31/428 ,  A61K31/433 ,  A61K31/44 ,  A61K31/4436 ,  A61K31/277 ,  A61K31/4439 ,  A61K45/06 ,  C07C255/60 ,  C07D263/32 ,  C07D277/28

CPC分类号： C07D417/04 ,  A61K31/155 ,  A61K31/175 ,  A61K31/277 ,  A61K31/4192 ,  A61K31/421 ,  A61K31/4245 ,  A61K31/426 ,  A61K31/428 ,  A61K31/433 ,  A61K31/44 ,  A61K31/4436 ,  A61K31/4439 ,  A61K45/06 ,  C07C247/18 ,  C07C255/57 ,  C07C255/60 ,  C07C311/37 ,  C07D213/81 ,  C07D249/06 ,  C07D249/08 ,  C07D263/32 ,  C07D271/06 ,  C07D277/26 ,  C07D277/28 ,  C07D277/30 ,  C07D277/56 ,  C07D277/66 ,  C07D285/08 ,  C07D285/12 ,  C07D291/04 ,  A61K2300/00

摘要： The present invention concerns compounds of general formula (I): in which Y and Z are chosen from CH and N; T is chosen from CO or SO2; n is 1 to 3; R1 represents a group chosen, for example, from C1-C3 alkyl chains unsubstituted or substituted by fluorine, the unsubstituted or substituted cyclic, cyano, azido, alkoxy and phenyl groups; and R is chosen from the azido, cyano, alkinyl and 2-benzothiazolyl groups and an optionally substituted aromatic heterocycle with five vertices; and the use thereof in the treatment of bacterial and mycobacterial infections such as, for example, tuberculosis, leprosy and atypical mycobacterial infections. The present invention also concerns pharmaceutical compositions comprising, as the active ingredient, at least one of the abovementioned compounds and optionally an antibiotic activatable via the EthA pathway.

公开(公告)号：US20180071289A1

公开(公告)日：2018-03-15

申请号：US15658211

申请日：2017-07-24

申请人： Motonari UESUGI ,  Salih J. WAKIL ,  Lutfi ABU-ELHEIGA ,  Mizuki WATANABE

发明人： Motonari UESUGI ,  Salih J. WAKIL ,  Lutfi ABU-ELHEIGA ,  Mizuki WATANABE

IPC分类号： A61K31/5025 ,  C07D213/06 ,  A61K31/426 ,  C07D417/14 ,  C07D417/04 ,  C07D487/04 ,  C07D277/24 ,  A61K31/4709 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  C07D213/76 ,  C07D235/14 ,  C07D417/12 ,  C07D277/22 ,  C07D213/16 ,  A61K31/437 ,  A61K31/427 ,  A61K31/428 ,  C07D471/04 ,  C07D277/66

CPC分类号： A61K31/5025 ,  A61K31/426 ,  A61K31/427 ,  A61K31/428 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/496 ,  C07D213/06 ,  C07D213/16 ,  C07D213/76 ,  C07D235/14 ,  C07D277/22 ,  C07D277/24 ,  C07D277/66 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

摘要： The present invention relates to methods of treating a disease related to cell hyper-proliferation via administration of a therapeutically effective amount of a compound having a general tripartite structure A-B-C. In the tripartite structure A, B, and C are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein. The methods may utilize particular compounds, for example, having a piperidinyl, a pyrrolinyl or pyridinyl A ring, a thiazole B ring, and a phenyl C ring which may be further substituted independently.

公开(公告)号：US20180055803A1

公开(公告)日：2018-03-01

申请号：US14930488

申请日：2015-11-02

申请人： CymaBay Therapeutics, Inc.

发明人： Brian Edward Lavan ,  Gopal Chandra Saha ,  Brian K. Roberts ,  Charles A. McWherter

IPC分类号： A61K31/216 ,  A61K31/426 ,  C07C59/68 ,  C07C233/47 ,  A61K31/192

CPC分类号： A61K31/216 ,  A61K31/192 ,  A61K31/426 ,  C07C59/68 ,  C07C233/47

摘要： Methods of treating gout flares comprising administering a composition comprising a first urate-lowering agent are disclosed. In some aspects, the first urate-lowering agent is (−)-halofenate, (−)-halofenic acid, or a pharmaceutically acceptable salt thereof. Other aspects provide for methods of reducing the number, duration, frequency or intensity of gout flares experienced by a subject.

公开(公告)号：US20180043014A1

公开(公告)日：2018-02-15

申请号：US15627694

申请日：2017-06-20

申请人： Celldex Therapeutics, Inc.

发明人： Michael E. Jeffers ,  William J. LaRochelle

IPC分类号： A61K39/395 ,  C07K16/30 ,  A61K31/506 ,  A61K45/06 ,  A61K31/4439 ,  A61K33/20 ,  A61K31/54 ,  A61K31/426 ,  A61K31/4706 ,  A61K31/454 ,  A61K31/52 ,  A61K31/35 ,  A61K31/5025

CPC分类号： A61K39/39558 ,  A61K31/35 ,  A61K31/426 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/4706 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/52 ,  A61K31/54 ,  A61K33/20 ,  A61K45/06 ,  A61K47/6803 ,  A61K47/6851 ,  C07K16/30 ,  C07K2317/21 ,  C07K2317/92 ,  A61K2300/00

摘要： The present invention relates to antibodies, including fully human monoclonal antibodies, with specificity to GPNMB, and uses of such antibodies. The present invention further provides compositions that increase expression of GPNMB on the surface of tumor cells, and methods of using such compositions to increase the anti-cancer activity or other therapeutic efficacy of the antibodies and immunoconjugates provided herein.